Frontiers in Endocrinology (May 2021)
Roles of Gut Microbial Metabolites in Diabetic Kidney Disease
- Qing Fang,
- Qing Fang,
- Qing Fang,
- Qing Fang,
- Qing Fang,
- Na Liu,
- Na Liu,
- Na Liu,
- Na Liu,
- Na Liu,
- Binjie Zheng,
- Binjie Zheng,
- Binjie Zheng,
- Binjie Zheng,
- Binjie Zheng,
- Fei Guo,
- Fei Guo,
- Fei Guo,
- Fei Guo,
- Fei Guo,
- Xiangchang Zeng,
- Xiangchang Zeng,
- Xiangchang Zeng,
- Xiangchang Zeng,
- Xiangchang Zeng,
- Xinyi Huang,
- Xinyi Huang,
- Xinyi Huang,
- Xinyi Huang,
- Xinyi Huang,
- Dongsheng Ouyang,
- Dongsheng Ouyang,
- Dongsheng Ouyang,
- Dongsheng Ouyang,
- Dongsheng Ouyang
Affiliations
- Qing Fang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Qing Fang
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Qing Fang
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Qing Fang
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Qing Fang
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, China
- Na Liu
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Na Liu
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Na Liu
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Na Liu
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Na Liu
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, China
- Binjie Zheng
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Binjie Zheng
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Binjie Zheng
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Binjie Zheng
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Binjie Zheng
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, China
- Fei Guo
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Fei Guo
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Fei Guo
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Fei Guo
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Fei Guo
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, China
- Xiangchang Zeng
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Xiangchang Zeng
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Xiangchang Zeng
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Xiangchang Zeng
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Xiangchang Zeng
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, China
- Xinyi Huang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Xinyi Huang
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Xinyi Huang
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Xinyi Huang
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Xinyi Huang
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, China
- Dongsheng Ouyang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Dongsheng Ouyang
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Dongsheng Ouyang
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Dongsheng Ouyang
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Dongsheng Ouyang
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha Duxact Biotech Co., Ltd., Changsha, China
- DOI
- https://doi.org/10.3389/fendo.2021.636175
- Journal volume & issue
-
Vol. 12
Abstract
Diabetes is a highly prevalent metabolic disease that has emerged as a global challenge due to its increasing prevalence and lack of sustainable treatment. Diabetic kidney disease (DKD), which is one of the most frequent and severe microvascular complications of diabetes, is difficult to treat with contemporary glucose-lowering medications. The gut microbiota plays an important role in human health and disease, and its metabolites have both beneficial and harmful effects on vital physiological processes. In this review, we summarize the current findings regarding the role of gut microbial metabolites in the development and progression of DKD, which will help us better understand the possible mechanisms of DKD and explore potential therapeutic approaches for DKD.
Keywords
- gut microbiota
- microbial metabolites
- diabetic kidney disease
- diabetes
- short-chain fatty acids
- Trimethylamine-N-oxide
